Back
TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2
Poster Presentation

TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2

American Society of Clinical Psychopharmacology (ASCP), May 2025.

View Presentation

Summary of Presentation:

  • TSND-201 is a non-hallucinogenic, rapid acting neuroplastogen that increases neurite outgrowth
  • Preclinical results demonstrate rapid, robust, and long-lasting benefit tests of PTSD, anxiety, depression

View Poster

News

The Latest From Transcend

Transcend Therapeutics Presents Positive Phase 2 Results of the Placebo-Controlled IMPACT-1 Study of PTSD at American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Supporting TSND-201 as a Rapid, Robust, and Long-Lasting Treatment for PTSD Read More
Press Release

Transcend Therapeutics Presents Positive Phase 2 Results of the Placebo-Controlled IMPACT-1 Study of PTSD at American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Supporting TSND-201 as a Rapid, Robust, and Long-Lasting Treatment for PTSD
TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2 Read More
Poster Presentation

TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2
TSND-201 Demonstrated Rapid, Robust, and Durable Therapeutic Efficacy in a Randomized, Placebo-Controlled Trial (IMPACT-1) for the Treatment of Post-Traumatic Stress Disorder Read More
Poster Presentation

TSND-201 Demonstrated Rapid, Robust, and Durable Therapeutic Efficacy in a Randomized, Placebo-Controlled Trial (IMPACT-1) for the Treatment of Post-Traumatic Stress Disorder
Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class Read More
Media

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class
Learn More